Long-acting cilostazol versus isosorbide mononitrate for patients with vasospastic angina: a randomized controlled trial.

Min Gyu KangJong-Hwa AhnJin-Yong HwangSeok-Jae HwangJin-Sin KohYongwhi ParkJae Seok BaeKook Jin ChunJeong Su KimJune Hong KimMin Ku Chon

Published in: Coronary artery disease (2024)

Long-acting cilostazol provided comparable control of angina and fewer adverse neurologic reactions within 4 weeks compared to ISMN. Long-acting cilostazol provides more intensive control of angina within 1 week, suggesting that it may be an initial choice for the treatment of VSA.

Keyphrases

coronary artery disease
coronary artery
percutaneous coronary intervention
randomized controlled trial
clinical trial
acute coronary syndrome
emergency department
combination therapy
decision making
gestational age
replacement therapy
adverse drug
drug induced